All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma.
aggressive B-cell lymphoma
all-oral treatment
low-dose chemotherapy
metronomic chemotherapy
relapsed/refractory DLBCL
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
01
2022
accepted:
07
04
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
Treatment options in patients (pts.) with advanced relapsed and refractory aggressive B-cell lymphoma are limited. Palliative all-oral chemotherapy regimens reduce in-patient visits and contribute to quality of life. The all-oral low-dose chemotherapy regimen TEPIP comprises the conventional chemotherapy agents trofosfamide, etoposide, procarbazine, idarubicin and prednisolone. Safety and efficacy of TEPIP was evaluated in an observational retrospective, single-center study at the University Medical Center Regensburg between 2010 and 2020. Treatment with TEPIP was applied for 7 or 10 days during a 28-days period. In a subgroup of fit and therapy-motivated pts. rituximab was added. End points were overall survival (OS) and progression free survival (PFS). Adverse events ≥ CTCAE grade III were reported. 35 highly pre-treated pts. with aggressive B-cell lymphoma were enrolled. Median age at TEPIP start was 67 years and 85% of pts. received TEPIP as ≥ third treatment line. Overall response rate (ORR) was 23% (CR 17%). Pts. benefited from additional rituximab administration (ORR 67%) and a lower number of pre-treatments (ORR 41%). The OS was 3.3 months (m) with a 1y-OS of 25.7% and the PFS amounted to 1.3 m with a 1y-PFS of 8.8%. OS and PFS were significantly prolonged in pts. that responded to treatment or additionally received rituximab. Adverse events were mainly hematological and occurred in 49% of pts. TEPIP was well-tolerated and induced respectable response in a difficult-to-treat patient cohort. In particular, the all-oral administration enables out-patient use with palliative intent.
Identifiants
pubmed: 35619924
doi: 10.3389/fonc.2022.852987
pmc: PMC9127443
doi:
Types de publication
Journal Article
Langues
eng
Pagination
852987Informations de copyright
Copyright © 2022 Fante, Felsenstein, Mayer, Gerken, Klinkhammer-Schalke, Herr, Vogelhuber, Reichle and Heudobler.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):262-9
pubmed: 20709662
Blood. 2006 Jan 1;107(1):265-76
pubmed: 16150940
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Indian J Hematol Blood Transfus. 2019 Jan;35(1):50-56
pubmed: 30828148
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood. 2016 Mar 17;127(11):1410-6
pubmed: 26755709
Acta Oncol. 1991;30(7):819-21
pubmed: 1764273
Lancet Oncol. 2012 Jul;13(7):696-706
pubmed: 22652183
J Clin Oncol. 2011 Apr 1;29(10):1342-8
pubmed: 21321299
Ann Oncol. 2011 Jul;22(7):1622-1627
pubmed: 21228334
Leuk Lymphoma. 2021 Sep;62(9):2161-2168
pubmed: 33764240
Clin Cancer Res. 2002 Jan;8(1):221-32
pubmed: 11801563
BMC Cancer. 2018 Oct 19;18(1):1000
pubmed: 30340554
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Lancet Oncol. 2011 May;12(5):460-8
pubmed: 21482186
Blood. 2010 Sep 23;116(12):2040-5
pubmed: 20548096
J Clin Invest. 2000 Apr;105(8):R15-24
pubmed: 10772661
Bioessays. 1991 Jan;13(1):31-6
pubmed: 1722975
Bone Marrow Transplant. 2017 Feb;52(2):216-221
pubmed: 27643872
Leuk Lymphoma. 2019 Jul;60(7):1610-1625
pubmed: 30702000
Bone Marrow Transplant. 2016 Jan;51(1):51-7
pubmed: 26367239
J Clin Oncol. 2014 Nov 1;32(31):3490-6
pubmed: 25267740
Nat Med. 2015 Aug;21(8):922-6
pubmed: 26193343
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
Med Clin North Am. 1976 Sep;60(5):1043-52
pubmed: 59842
Blood. 2015 Aug 6;126(6):733-8
pubmed: 26109202
Clin Cancer Res. 2013 Apr 1;19(7):1660-9
pubmed: 23339126
Eur J Cancer. 1997 Mar;33(3):500-2
pubmed: 9155539
Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):462-6
pubmed: 21859554
J Clin Oncol. 2010 Sep 20;28(27):4184-90
pubmed: 20660832
N Engl J Med. 1995 Dec 7;333(23):1540-5
pubmed: 7477169
Leuk Lymphoma. 1993;10 Suppl:65-72
pubmed: 8481673
Lancet Oncol. 2020 Jul;21(7):978-988
pubmed: 32511983
Lancet Oncol. 2006 May;7(5):379-91
pubmed: 16648042
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Curr Oncol. 2009 Mar;16(2):7-15
pubmed: 19370174
J Am Geriatr Soc. 1984 Apr;32(4):269-73
pubmed: 6368652
Invest New Drugs. 2019 Jun;37(3):548-558
pubmed: 31028663
N Engl J Med. 1993 Apr 8;328(14):1002-6
pubmed: 7680764
Cancer. 2008 May 15;112(10):2228-32
pubmed: 18338745
Ann Oncol. 2007 Jan;18 Suppl 1:i3-i8
pubmed: 17311819
Leuk Lymphoma. 2016 Aug;57(8):1823-30
pubmed: 26666433
Am J Hematol. 2019 Aug;94(8):E209-E213
pubmed: 31056762
Invest New Drugs. 1986;4(3):263-7
pubmed: 3469170
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Lett. 2015 Mar 28;358(2):100-106
pubmed: 25541061
J Clin Oncol. 2010 Apr 20;28(12):2094-100
pubmed: 20308668
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Med Sci (Basel). 2021 Jan 30;9(1):
pubmed: 33573146
J Clin Oncol. 2020 Jan 10;38(2):155-165
pubmed: 31693429
Haematologica. 2013 Nov;98(11):1726-31
pubmed: 23753028
Blood. 2021 Apr 1;137(13):1832-1835
pubmed: 33156925
J Clin Oncol. 2008 Oct 20;26(30):4952-7
pubmed: 18606983
Crit Rev Oncol Hematol. 2000 Aug;35(2):95-100
pubmed: 10936466
Blood. 1994 Mar 1;83(5):1165-73
pubmed: 8118021